Skip to main content
. Author manuscript; available in PMC: 2023 Aug 1.
Published in final edited form as: Int J Gynecol Cancer. 2022 Aug 1;32(8):1017–1024. doi: 10.1136/ijgc-2022-003430

Figure 2: Tumor molecular profiling and immunofluorescence analysis of ovarian clear cell carcinomas (OCCCs) treated with immune checkpoint blockade (ICB).

Figure 2:

A: Somatic mutations identified in OCCC using MSK-IMPACT targeted sequencing, including those with a durable clinical response (n = 4, green), and those without a durable clinical response (n = 12, navy). Only pathogenic mutations are shown. Genetic alterations are color-coded according to the legend. Indel, small insertion and deletion. TMB, tumor mutation burden.

B-C: Multiplex immunofluorescence analysis of tumor samples from Patient 3 (B) and Patient 10 (C), both of whom achieved a durable clinical benefit from ICB. Markers as indicated in the figures. CK, cytokeratin. Scale bars, 100 μm.